THE IMMUNOLOGICAL ADJUVANT AND VACCINE CARRIER PROPERTIES OF LIPOSOMES

被引:44
作者
GREGORIADIS, G
机构
[1] Centre for Drug Delivery Research, The School of Pharmacy, University of London, London, WC1N 1AX
关键词
LIPOSOMES; ANTIGENS; IMMUNE RESPONSE; IMMUNOLOGICAL ADJUVANT; VACCINES;
D O I
10.3109/10611869408996809
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Animal immunization studies by numerous laboratories have shown that liposomes promote humoural and cell-mediated immunity to a wide spectrum of bacterial, protozoan and viral antigens as well as tumour cell antigens, venoms and allergens. Adjuvanticity depends on liposomal structural characteristics which determine vesicle fate in vivo and, thus, the mode of antigen interaction with antigen-presenting cells. Adjuvanticity is further promoted by receptor mediated targeting of liposomes to macrophages, or the presence of other adjuvants including cytokines. The immunoadjuvant function of liposomes is supplemented by their ability to act as a carrier for co-entrapped B and T-cell epitopes, thus eliminating the need for a carrier protein. Recently, a technique has been developed for the entrapment of live or attenuated microbial vaccines into giant liposomes under conditions which retain their viability. Liposomes containing microbial vaccines (together with other soluble antigens or cytokines) could be used as carriers of vaccines in cases where there is a need to prevent interaction of vaccines with maternal antibodies or preformed antibodies to vaccine impurities.
引用
收藏
页码:351 / 356
页数:6
相关论文
共 56 条
[42]  
MIMMS CA, 1993, MED MICROBIOLOGY, pCH36
[43]  
MONTE PD, 1989, J IMMUNOL, V142, P1437
[44]   SOLUBLE-PROTEINS DELIVERED TO DENDRITIC CELLS VIA PH-SENSITIVE LIPOSOMES INDUCE PRIMARY CYTOTOXIC LYMPHOCYTE-T RESPONSES INVITRO [J].
NAIR, S ;
ZHOU, F ;
REDDY, R ;
HUANG, L ;
ROUSE, BT .
JOURNAL OF EXPERIMENTAL MEDICINE, 1992, 175 (02) :609-612
[45]  
PARTIDOS CD, 1992, IMMUNOLOGY, V77, P262
[46]   ENHANCED ANTIBODY-RESPONSE TO LIPOSOME-ASSOCIATED PROTEIN ANTIGENS - PREFERENTIAL STIMULATION OF IGG2A/B PRODUCTION [J].
PHILLIPS, NC ;
EMILI, A .
VACCINE, 1992, 10 (03) :151-158
[47]  
REDDY R, 1992, J IMMUNOL, V148, P1585
[48]  
SHAHUM E, 1988, IMMUNOLOGY, V65, P315
[49]  
SHEK PN, 1984, IMMUNOTOXICOLOGY, P103
[50]  
SU D, 1989, IMMUNOLOGY, V66, P466